The deal gives Moderna access to Generation Bio’s proprietary drug delivery system and DNA technology to develop drugs targeting immune cells and the liver.
https://www.pharmalive.com/wp-content/uploads/2022/10/ReutersModerna10-1-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-03-23 07:33:272023-03-23 09:07:30Moderna, Generation Bio enter licensing deal for genetic medicines
